Speakers

Prof. Chao-Nan (Miles) Qian

Sun Yat-sen University Cancer Center, China


 

Prof. Francesco Pezzella

John Radcliffe Hospital, University of Oxford, UK


Prof. Raffaella Giavazzi

Mario Negri Institute for Pharmacological Research, Italy


Choice of chemotherapy regimens to accompany antiangiogenic treatments

Raffaella Giavazzi was born in Bergamo, Italy. She is Head of the Laboratory of Biology and Treatment of Metastasis at the Mario Negri Institute for Pharmacological Research (since 1993).
more ... 

Raffaella Giavazzi was born in Bergamo, Italy. She is Head of the Laboratory of Biology and Treatment of Metastasis at the Mario Negri Institute for Pharmacological Research (since 1993).

She obtained her Biological Sciences degree (1979) and her PhD in Pharmacology (1984) at the University of Milan, Italy and the Qualification of Professor in General Pathology and in Applied Biology (2017). She was a post-doc Fellow in the Cancer Metastasis and Treatment Laboratory, NCI-FCRDC, Frederick, MD (1981-‘83), Assistant Professor at the Dept. of Cell Biology of M.D. Anderson Hospital and Tumour Institute, University of Texas in Houston (1983-‘85). She was Honorary Research Fellow and Visiting Professor, Richard Dimble Dept. of Cancer/ICRF, London, UK (1996).

She was adjutant Professor in Oncology at the Medical School of the University of Brescia (2007-‘10) and at the Medical School of the University of Pisa (1999-2010). Since 2012 she is member of the Board of Directors at the University of Trento.

She was consulting scientist for the NCI-Drug Therapeutics Program, USA (1996-2006) and a member of the Executive Committee at the South Europe New Drug Development Organization (1988-2012).

She was in the board (1994-2004) and President (2005-2007) of the Italian Cancer Society, in the board of the European Association for Cancer Research (2008-2012) and of the International Metastasis Research Society (2000-2004). She is member of the American Association for Cancer Research (AACR).

She received the Researcher Career Award “Italian League Against Tumor” (2003) and the “Giorgio Prodi” Lecturship at the Italian Cancer Society (2012).

Raffaella Giavazzi’s research interests are in the field of tumor biology and pharmacology, with a specific interest in the metastatic process and angiogenesis. She is involved in the pre-clinical and clinical development of new therapeutic strategies against cancer.

She has published approximately 200 articles in the field of Cancer Research and communicated approximately 400 studies in national and international congresses.


 

Dr. Manuel Valiente

Brain Metastasis Group at CNIO, Spain


Vascular co-option in brain metastasis: molecular mediators and functional implications

Manuel Valiente (Zaragoza, 1980) has a degree in Veterinary Medicine (1998-2003, Zaragoza) awarded with the Extraordinary Degree Award and the second National Award in Veterinary Medicine.
more ... 
Manuel Valiente (Zaragoza, 1980) has a degree in Veterinary Medicine (1998-2003, Zaragoza) awarded with the Extraordinary Degree Award and the second National Award in Veterinary Medicine.

His interest in the Central Nervous System led him to earn a doctorate in Neuroscience (Instituto de Neurociencias, Alicante, 2005-2009). In the laboratory of Oscar Marín he developed several projects to understand the principles that govern migration of neuronal precursors needed to establish neuronal circuits in the brain. His doctoral work produced seven publications in leading journals in the field (Development, Journal of Neuroscience, Nature) and received the Extraordinary Doctoral Award. To expand his scientific expertise, while maintaining his research within the nervous system, Manuel joined the laboratory of Joan Massagué (MSKCC, New York, 2010-2014). Manuel′s interest focused on finding critical mediators of metastasis specifically required for the initial colonization of metastatic cells in the brain parenchyma. The most significant contributions of this period were the discovery of the molecular basis of high inefficiency during metastatic brain colonization and the identification of a cell adhesion molecule critical for vascular co-option. More recently he has participated in the first proof-of-concept validating experimental therapies against brain related survival mechanisms of metastasis (Nature, 2016), which is now in clinical trials.

Manuel established the Brain Metastasis Group at CNIO in March 2015, where he leads a team of scientists whose goal is to discover critical aspects of the biology of brain metastasis in order to develop new therapeutic opportunities. During this time Manuel has received several awards for his scientific contributions, attracted competitive grants and participated as invited speaker in basic and clinical meetings of brain tumors. His laboratory is interested in finding novel brain metastasis mediators, improve experimental models to incorporate therapies and explore novel methods to target established brain metastasis. All these aims consider the specificity of the brain environment as a critical component to understand the biology of this progression of cancer.


 

Prof. Shijie Cai

Nuffield Division of Clinical Laboratory Sciences, Oxford University, UK


Cancer-associated fibroblast extracellular vesicles and tumour angiogenesis

Shijie Cai obtained his first degree at Tongji Medical University in Medicine in 1985 and worked as a Paediatricain at Fujian Women & Children’s Hospital, China till 1992.
more ... 
Shijie Cai obtained his first degree at Tongji Medical University in Medicine in 1985 and worked as a Paediatricain at Fujian Women & Children’s Hospital, China till 1992. He completed his Master degree at Liverpool University in Medical Microbiology in 1993 and worked as a Clinical Research Fellow at Alder-Hey Children’s Hospital, Liverpool in Paediatric ICU in 1994. In 1996, he was awarded a fellowship by Cambridge Overseas Trust to study for a doctorate at Cambridge University in Gene Therapy. Following a post doc in Oxford in 1999, he becomes a qualified Clinical Virologist in 2005 and established a group at the Department of Clinical Pharmacology, Oxford University in 2007. He received an Angiogenesis Gordon Research Conference prize award at Salve Regina University, USA in 2009. Currently, he is a Senior Research Associate of Professor David Kerr’s group, Nuffield Division of Clinical Laboratory Sciences, Oxford University. He is a Visiting Professor of National Huaqiao University in 2010 and Xiamen University in 2016.

He leads some research projects in the area of tumour angiogenesis, tumour initiation and metastasis, being interested in the tumour microenvironment, drug resistance and targeted drug development.

Some methods have been developed in the group including gene editing (CRISPR/Cas9) and an integrated metabolomcs and genomics analysis to identify cancer targets.


 

Prof. Jose Iglesias

Medical & Clinical Affairs at Apobiologix in Toronto, Canada


Integration of angiogenesis and tumor microenvironment markers in randomized clinical trials

 

Dr.Jackeline Agorreta

Center of Applied Medical Research (CIMA)-University of Navarra, Spain


Effects of targeted therapies and immunotherapy on lung cancer blood vessels

 

Prof. Robert Kerbel

University of Toronto, Canada


Anti-vascular strategies under development to target co-opted tumor blood vessels in metastases

Prof. Robert Kerbel received his PhD in immunology in 1972 from the Dept. of Immunology & Microbiology, Queen’s University, Kingston, Ontario, Canada, after which he undertook postdoctoral training in London at the Institute for Cancer Research in tumor immunology.
more ... 
Prof. Robert Kerbel received his PhD in immunology in 1972 from the Dept. of Immunology & Microbiology, Queen’s University, Kingston, Ontario, Canada, after which he undertook postdoctoral training in London at the Institute for Cancer Research in tumor immunology. He started his independent research program in 1975 studying tumor immunology and metastasis at Queen's, and was appointed Director of the Cancer Biology Program in the Dept. of Pathology in 1981. In 1985 he was recruited as Director of Cancer Biology Research at Mt. Sinai Hospital, Toronto. He then moved to Sunnybrook Health Sciences Centre to assume the same position from 1991 until 2001. Dr. Kerbel held a Canada Research Chair in Tumor Biology, Angiogenesis & Antiangiogenic Therapy (2001-2015), and is a professor in the Dept. of Medical Biophysics at the University of Toronto, and Senior Scientist at the Sunnybrook Research Institute. His overall main research interest has been devising new cancer treatment strategies having improved efficacy and reduced toxicity for the treatment of metastatic disease. This culminated in his translational studies of combinatorial low-dose ‘metronomic’ chemotherapy with antiangiogenic drugs. Other major contributions include development of improved preclinical investigational therapeutic models in mice involving early stage or advanced metastatic disease, uncovering mechanisms by which antiangiogenic drugs increase chemotherapy efficacy, and elucidating mechanisms of intrinsic or acquired antiangiogenic drug resistance. His current major research interests include assessment of the significance of ‘vessel co-option’ in tumors on response to antiangiogenic drugs, and combination therapy utilizing immune checkpoint inhibitors with VEGF (or ang2) targeting antiangiogenic drugs, using new mouse models for immune therapy his lab is developing. He has published 423 papers, given 874 invited lectures around the world. Among the awards he has received include the 2004 Canadian Cancer Society Robert Noble Award for Excellence in Cancer Research, the Breast Cancer Research Award from the European Institute of Oncology in 2008, a Man of Distinction Honor by the Israel Cancer Research Fund in 2011, and the Colin Thomson Memorial Medal for achievements in cancer research from Worldwide Cancer Research in 2013.


 

Prof. Raymond L. Barnhill

University of Paris Descartes, France

Prof.Raymond L. Barnhill is currently Professor of Pathology at the Institut Curie, and the Faculty of Medicine, University of Paris Descartes, Paris, France. Dr. Barnhill received his MD degree from Duke University and was a postdoctoral fellow and graduate student in the University of Oxford.
more ... 
Prof.Raymond L. Barnhill is currently Professor of Pathology at the Institut Curie, and the Faculty of Medicine, University of Paris Descartes, Paris, France. Dr. Barnhill received his MD degree from Duke University and was a postdoctoral fellow and graduate student in the University of Oxford. He has trained as a dermatologist, anatomic pathologist, and dermatopathologist. His research interests have largely included the biology of melanocytic lesions and melanoma, angiogenesis, mechanisms of metastasis, especially angiotropism and extravascular migratory metastasis with Dr. Claire Lugassy. He has held major academic leadership appointments including Director of Dermatopathology at Brigham and Women’s Hospital and Children’s Hospital, Harvard Medical School, and Director of Dermatopathology (tenured professor) at Johns Hopkins University. Dr. Barnhill has founded both the North American Melanoma Pathology Study Group and in 2007 the International Melanoma Pathology Study Group, of which he is currently President. He has also been an active member of the WHO Melanoma Program, the EORTC Melanoma Group, the AJCC expert panels for melanoma and ophthalmology, and other professional societies. In 2011, he received the Founder’s Award from the American Society of Dermatopathology. Dr. Barnhill is the author of a number of original articles, chapters, and reviews, and the author, co-author, or editor of five books, including three leading textbooks in dermatopathology and the pathology of melanoma.


 

Prof. Peter B Vermeulen


The emerging clinical utility of the histopathological growth patterns of liver metastases as a biomarker of vessel co-option or angiogenesis

Prof.Peter Vermeulen is a pathologist (MD, PhD) who focuses on the vascularisation of primary and metastatic breast and colorectal carcinomas, mainly by histopathological analysis.
more ... 
Prof.Peter Vermeulen is a pathologist (MD, PhD) who focuses on the vascularisation of primary and metastatic breast and colorectal carcinomas, mainly by histopathological analysis. To this purpose, he has written several guidelines to quantify the amount of blood vessels in tissue sections and to recognise the type of vascularisation. Work of his team in Antwerp (Belgium) has led to the description of the histopathological growth patterns of liver metastases and this now allows for the distinction between sprouting angiogenesis and (non-angiogenic) vessel co-option as a means of tumor vascularisation. He is currently trying to establish the clinical utility of the histopathological growth patterns to predict survival or response to treatment in patients with liver metastases in an international collaborative study. Also, his team is developing surrogate markers of the histopathological growth patterns. Medical imaging algorithms (CT, MRI, US) can probably be designed to detect the type of vascularisation of a tumor in the liver, brain or lungs in an individual patient, at the start of treatment and on treatment. The hypothesis is that this will facilitate the implementation of patient-tailored treatment strategies by a more precise prediction of intrinsic and acquired resistance in patients with colorectal cancer liver metastases. The currently used clinical risk scores indeed often fail to provide accurate information. Last but not least, Dr Vermeulen’s team is trying to understand the biology of vessel co-option by, for example, investigating the association of the histopathological growth patterns and the immune phenotype of colorectal and breast cancer liver metastases.


 

Dr. Claire Lugassy

Institut Curie Research Center, France


 

Dr. Giorgio Seano

Institut Curie Research Center, France


Vessel co-option in glioblastoma: spy it, find the target and shoot

Dr. Giorgio Seano (1982, Turin, Italy) is the Head of the Tumor Microenvironment Lab in Institut Curie Research Center, Orsay-Paris
more ... 
Dr. Giorgio Seano (1982, Turin, Italy) is the Head of the Tumor Microenvironment Lab in Institut Curie Research Center, Orsay-Paris (France). His scientific interests are tumor angiogenesis, vessel co-option, cell migration and radioresistance.
Dr. Seano received his PhD in “Complex Systems in Life Science” in 2010 from University of Turin, Italy. During his PhD training and his first postdoc period in Italy, (a) he investigated tumor angiogenesis and integrins, (b) he provided the first evidence of a new sub-cellular structure – the endothelial podosome rosette – that controls blood vessel branching during sprouting angiogenesis and (c) developed the first ex vivo human knock-down angiogenesis assay.
In 2012, he joined the laboratory of Dr. Rakesh K. Jain in Harvard Medical School (Boston) and focused his research on tumor microenvironment, brain tumors and intravital microscopy. Specifically, he investigated (a) physical forces from brain tumors and their effects on neuro-vascular functions and (b) vessel co-option in glioblastoma.
In 2017, he was selected as a Junior Group Leader in Institut Curie and he is now setting up his new laboratory.
Dr. Seano authored 26 articles, presented 16 seminars on his research, reviewed 15 papers and received 2 prestigious prizes, 2 travel grants and 5 competitive fellowships/grants for his studies.


 

Dr Jiangting Hu

Radcliffe Department of Medicine, University of Oxford, UK


Molecular Genomic Approach to the Identification of Predictive Biomarker of Colorectal Cancer in Response to Bevacizumab

Dr Jiangting Hu obtained her bachelor degree in medicine in 1985 and her master degree in public health in 1988 at Shanghai Medical University in Shanghai, China.
more ... 
Dr Jiangting Hu obtained her bachelor degree in medicine in 1985 and her master degree in public health in 1988 at Shanghai Medical University in Shanghai, China. Since 1992, she worked as a research fellow in biological science at University College London, Imperial College, Wellcome Trust Centre for Human Genetics in Oxford. She joined in Professor Francesco Pezzella’s group in 2001 embarking on journey to cancer angiogenesis research using molecular genomic profiling on non-small cell lung cancer. Dr Hu published her influential research article on molecular fingerprints of angiogenic versus non-angiogenic lung cancer in Oncogene in 2005 and awarded DPhil at Wolfson College, University of Oxford in 2006. Dr Hu received merit award for excellent research performance 2006, Nuffield Department of Clinical Laboratory Sciences, University of Oxford. Since then, she has been instrumental in numerous research projects including the role of mitochondrial chaperon TRAP1 in angiogenesis and tumorigenesis; Stratification of early detected lung cancer by molecular profiling; Identification of predictive biomarkers for anti-angiogenesis treatment in colorectal cancer. She also plays a key role in the study of myocardial metabolic and genomic in cardiac hypertrophy. She is now a senior research scientist of Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford.


 

Prof. Guoquan Gao

Zhongshan School of Medicine, Sun Yat-Sen University, China


Effects and mechanism of endogenous inhibitors on cancer angiogenesis and lymphangiogenesis.

Prof. Yihai Cao

Karolinska Institute, Sweden

 

Prof. Bruno Péault
 

image

  image



image

 

  The 4th International Meeting on Cancer and Blood Vessels